- Comera Life Sciences ( NASDAQ: CMRA ) is trading 6.1% higher after it announced positive data from Sequrus study.
- The company said preclinical data showed that its caffeine-based SQore excipient did not result in local or systemic toxicity and had no impact on any measured pharmacokinetic parameters of ipilimumab when administered under the skin.
- Comera is using its formulation platform SQore to enable subcutaneous ( SQ ) delivery of IV drugs such as monoclonal antibodies.
- "Based on our four preclinical studies completed to date with our lead excipient, we believe that our technology has the potential to bring the freedom of self-administration to existing life-changing therapies," the company said.
- The results also showed that caffeine had no impact on ipilimumab (branded as Yervoy to treat skin cancer) half-life and no effect on pharmacokinetic data for both the IV and SQ groups.
For further details see:
Comera Life Sciences rises on positive preclinical data from Sequrus study